Oncogenic Nras signaling in leukemic stem cell transformation
白血病干细胞转化中的致癌 Nras 信号传导
基本信息
- 批准号:9234062
- 负责人:
- 金额:$ 38.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-03-01 至 2021-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAllelesBiochemicalBloodCISH geneCell ProliferationCell physiologyClonal ExpansionDefectDiseaseEpigenetic ProcessExperimental ModelsGeneticGenetic TranscriptionGoalsHematopoietic NeoplasmsHematopoietic stem cellsHumanInduced MutationJAK2 geneKnock-outKnockout MiceKnowledgeLeadMalignant NeoplasmsMediatingModelingMolecularMusMutateMutationMyeloproliferative diseaseNeoplastic Cell TransformationOncogenesOncogenicOncoproteinsPopulationPreleukemiaProcessRelapseResearchRoleSignal TransductionStem cellsSuppressor GenesTestingTumor Suppressor Genesbasecell transformationdesigngenetic analysisinnovationleukemialeukemic stem cellleukemogenesismutantnew therapeutic targetnovel therapeutic interventionoverexpressionprogenitorself-renewalsmall molecular inhibitortargeted treatmenttherapy development
项目摘要
ABSTRACT
Mutations of oncogenes and tumor suppressor genes transform normal hematopoietic stem
cells (HSC) into leukemic stem cells (LSC) in a multi-step process. As the first step of
leukemogenesis, the “pre-leukemia” mutations dys-regulate HSC functions to promote clonal
expansion by increasing proliferation, competitiveness and self-renewal. Pre-LSCs are further
transformed into LSCs by additional mutations. Targeting pre-LSCs and LSCs has the potential
to eliminate leukemia. Although many oncogenes and tumor suppressor genes have been
proposed to transform normal HSCs to LSCs, very little is known about what signaling
mechanism underlies this transformation to allow development of therapies to target pre-LSCs
and LSCs. The long term goal of our research is to identify signaling mechanisms through which
oncogenes and tumor suppressor genes transform normal HSCs into LSCs. Clonal expansion
has been difficult to recapitulate experimentally because mutations that drive HSCs into cycling
often lead to reduced HSC self-renewal and HSC depletion. We recently found that an
oncogenic Nras mutation commonly found in human leukemias, G12D, dys-regulates HSCs and
transform them into pre-LSC with increased proliferation, competitiveness and self-renewal. The
objective of this proposal is to identify the signaling mechanism underlying this Nras induced
transformation. Based on our preliminary results, our central hypothesis is that JAK2/STAT5
signaling is critical in the Nras induced transformation to pre-LSCs and further mediates
transformation to LSCs. We will test this hypothesis by 1) Identify the mechanism by which
NrasG12D activates STAT5 to dys-regulate HSC functions; 2) Define the role of JAK2 in NrasG12D
induced HSC dys-regulation and 3) determine the role of JAK2/STAT5 signaling in fully
transformed LSCs. The approach is innovative because 1) it takes advantage of our newly
developed clonal expansion model; 2) it combines mouse genetic analysis and cellular and
biochemical analysis on rare populations to investigate signaling mechanisms in pre-LSCs and
LSCs, and 3) it evaluates the role of non-canonical Ras effectors that may be responsible for
the effects of oncogenic Ras in a population highly relevant to leukemogenesis. The proposed
research is significant because it is expected to advance knowledge of the signaling
mechanisms underlying the transformation from normal HSCs to LSCs, and therefore to inform
novel therapeutic intervention that will target pre-LSCs and LSCs to eradicate leukemia.
摘要
癌基因和抑癌基因突变转化正常造血干细胞
白血病干细胞(LSC)是一个多步骤的过程。作为第一步
在白血病发生中,“白血病前”突变失调HSC功能,促进克隆形成。
通过增加扩散、竞争力和自我更新来实现扩张。Pre-LSC更进一步
通过额外的突变转化为LSC。靶向pre-LSC和LSC有可能
来消除白血病尽管许多癌基因和肿瘤抑制基因已经被
提出将正常HSC转化为LSC,关于什么信号传导知之甚少。
这种转变的基础机制允许开发靶向前LSC的疗法
和LSC。我们研究的长期目标是确定信号机制,
癌基因和肿瘤抑制基因将正常HSC转化为LSC。克隆扩增
很难在实验上重现,因为驱动HSC进入循环的突变
通常导致HSC自我更新减少和HSC耗竭。我们最近发现,
在人类白血病中常见的致癌Nras突变,G12 D,使HSC失调,
将其转变为具有更高扩散性、竞争力和自我更新能力的准地方供应链。的
该建议的目的是确定Nras诱导的信号转导机制
转型基于我们的初步结果,我们的中心假设是JAK 2/STAT 5
信号传导在Nras诱导的向前LSC的转化中是关键的,并进一步介导
转化为LSC。我们将通过以下方式检验这一假设:1)确定
NrasG 12 D激活STAT 5以失调HSC功能; 2)定义JAK 2在NrasG 12 D中的作用
诱导的HSC失调和3)确定JAK 2/STAT 5信号传导在完全调节HSC中的作用。
转化的LSC。这种方法是创新的,因为1)它利用了我们新的
发展了克隆扩增模型; 2)它结合了小鼠遗传分析和细胞,
对稀有群体进行生物化学分析,以研究前LSC中的信号传导机制,
LSC,和3)它评估了可能负责LSC的非典型Ras效应子的作用。
致癌Ras在与白血病发生高度相关的人群中的作用。拟议
这项研究是重要的,因为它有望提高对信号的认识,
从正常HSC向LSC转化的潜在机制,因此,
新的治疗干预将靶向前LSC和LSC以根除白血病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Qing Li其他文献
Qing Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Qing Li', 18)}}的其他基金
The role of ER associated degradation (ERAD) in hematopoietic stem cells
ER相关降解(ERAD)在造血干细胞中的作用
- 批准号:
10187650 - 财政年份:2020
- 资助金额:
$ 38.75万 - 项目类别:
The role of ER associated degradation (ERAD) in hematopoietic stem cells
ER相关降解(ERAD)在造血干细胞中的作用
- 批准号:
10454963 - 财政年份:2020
- 资助金额:
$ 38.75万 - 项目类别:
The role of ER associated degradation (ERAD) in hematopoietic stem cells
ER相关降解(ERAD)在造血干细胞中的作用
- 批准号:
10649697 - 财政年份:2020
- 资助金额:
$ 38.75万 - 项目类别:
Oncogenic Nras signaling in leukemic stem cell transformation
白血病干细胞转化中的致癌 Nras 信号传导
- 批准号:
9028457 - 财政年份:2016
- 资助金额:
$ 38.75万 - 项目类别:
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
致癌 Ras 在白血病发生和靶向治疗反应中的作用
- 批准号:
7923173 - 财政年份:2008
- 资助金额:
$ 38.75万 - 项目类别:
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
致癌 Ras 在白血病发生和靶向治疗反应中的作用
- 批准号:
7509983 - 财政年份:2008
- 资助金额:
$ 38.75万 - 项目类别:
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
致癌 Ras 在白血病发生和靶向治疗反应中的作用
- 批准号:
8332887 - 财政年份:2008
- 资助金额:
$ 38.75万 - 项目类别:
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
致癌 Ras 在白血病发生和靶向治疗反应中的作用
- 批准号:
7681712 - 财政年份:2008
- 资助金额:
$ 38.75万 - 项目类别:
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
致癌 Ras 在白血病发生和靶向治疗反应中的作用
- 批准号:
8116544 - 财政年份:2008
- 资助金额:
$ 38.75万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 38.75万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 38.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 38.75万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 38.75万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 38.75万 - 项目类别: